capmatinib

Also known as INC280, INCB28060, Tabrecta

Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.

Key facts

Drug.O: 1
Drug.image: Capmatinib.svg
Drug.image_class: skin-invert-image
Drug.tradename: Tabrecta
Drug.MedlinePlus: a620038
Drug.DailyMedID: Capmatinib
Drug.pregnancy_category: Not recommended
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L01
Drug.ATC_suffix: EP01
Drug.legal_CA: Rx-only
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.CAS_number: 1029712-80-8
Drug.PubChem: 25145656
Drug.DrugBank: DB11791
Drug.ChemSpiderID: 25069712
Drug.UNII: TY34L4F9OZ

via Wikipedia infobox

Research

314 papers

Capmatinib.2012
Capmatinib.2006
Capmatinib: First Approval.Drugs · 2020
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.The New England journal of medicine · 2020
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.The Lancet. Oncology · 2024

via PubMed

Wikidata facts

Mass: 412.144787

Show 4 more facts

canonical SMILES: CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
chemical formula: C₂₃H₁₇FN₆O
World Health Organisation international non-proprietary name: capmatinib
Commons category: Capmatinib

Sources (6)

via Wikidata · CC0

~5 min read